Oral Presentation to Include Positive Interim Results from Its Ongoing Phase 2 Trial of Bertilimumab in Bullous Pemphigoid
ENGLEWOOD CLIFFS, NJ / ACCESSWIRE / January 10, 2018 / Immune Pharmaceuticals Inc. (IMNP) (the "Company"), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that an abstract detailing positive interim results from the Company's ongoing phase 2 trial of bertilimumab in bullous pemphigoid has been accepted for presentation at the Late-Breaking Research Forums during the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego, CA. Presentation of data from the study, A Pilot Phase 2a Study of the Safety and Efficacy of Bertilimumab, an Anti-Eotaxin-1 Antibody, in Bullous Pemphigoid, will take place in an oral session on Saturday, February 17, between 1:00-3:00 PM PST.
"We are honored that these interim results will be presented such a large and prestigious forum," said Tony Fiorino, MD, PhD, Chief Medical and Operating Officer of Immune Pharmaceuticals. "We look forward to completing this study and advancing the development of bertilimumab in bullous pemphigoid, in order to offer a new treatment option to patients suffering from this challenging blistering disease."
The AAD is the largest and most influential and representative dermatology group in the United States. It represents virtually all practicing dermatologists in the United States as well as a growing number of international dermatologists. Approximately 19,000 attendees will attend the AAD Annual Meeting this year.
About Immune Pharmaceuticals Inc.
Immune Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Immune's lead program, bertilimumab, is a first-in-class, fully human monoclonal antibody that targets and lowers levels of eotaxin-1, a chemokine that plays a role in immune responses and attracts eosinophils to the site of inflammation. By neutralizing eotaxin-1, bertilimumab may prevent the migration of eosinophils and other cells, thus helping to relieve associated inflammatory conditions. Currently, Immune is conducting two phase 2 clinical trials to test bertilimumab in patients suffering from bullous pemphigoid and ulcerative colitis, respectively. Bertilimumab may have application in other diseases, including atopic dermatitis, immune and inflammatory hepatitis, and asthma.
Safe Harbor Statements Regarding Forward-Looking Statements
The statements in this news release made by representatives of Immune relating to matters that are not historical facts, including without limitation, those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Immune's product candidates and the sufficiency of Immune's cash and other capital resources, the continued development by Immune of bertilimumab or its determination to seek Orphan Drug designation for the pharmaceutical product of bertilimumab are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, or Immune's ability to fund such efforts with or without partners. Immune undertakes no obligation to update any of these statements. In addition, there can be no assurance that Immune will successfully complete its anticipated corporate restructuring, or that Immune will be able to reduce expenses, capitalize on strategic alternatives, develop its assets, and generate value for shareholders. Immune may, at any time and for any reason until the proposed spin-off is complete, abandon the spin-off or modify its terms and conditions, or consider competing, alternate or complimentary transactions or offers by third parties at the discretion of Immune's board of directors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Immune's filings with the Securities and Exchange Commission, including those discussed in Immune's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and periodic reports filed on Form 8-K.
For further information, contact: email@example.com
SOURCE: Immune Pharmaceuticals Inc.